@Article{Shahar_etal2017,
author="Shahar, T.
and Rozovski, U.
and Hess, K.R.
and Hossain, A.
and Gumin, J.
and Gao, F.
and Fuller, G.N.
and Goodman, L.
and Sulman, E.P.
and Lang, F.F.",
title="Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival",
journal="Neuro-Oncology",
year="2017",
volume="19",
number="5",
pages="660--668",
optkeywords="*glioblastoma",
optkeywords="*mesenchymal stem cells",
optkeywords="*microenvironment",
optkeywords="*prognosis",
abstract="Background: Human mesenchymal stem cells (hMSCs) have been shown to reside as stromal cells in human gliomas as glioma-associated hMSCs (GA-hMSCs), but their biological role remains unclear. Because recent evidence indicates that GA-hMSCs drive tumor cell proliferation and stemness, we hypothesized that a higher percentage of GA-hMSCs in tumors predicts poor patient prognosis. Method: We determined the percentage of cells coexpressing GA-hMSC markers CD105+/CD73+/CD90+ from patients with newly diagnosed high-grade glioma and analyzed the association between this percentage and overall survival (OS) in 3 independent cohorts: fresh surgical glioblastoma specimens (cohort 1, N = 9), cultured tumor specimens at passage 3 (cohort 2, N = 28), and The Cancer Genome Atlas (TCGA) database. Results: In all cohorts, patient OS correlated with the percentages of GA-hMSCs in tumors. For cohort 1, the median OS of patients with tumors with a low percentage of triple-positive cells was 46 months, and for tumors with a high percentage of triple-positive cells, it was 12 months (hazard ratio [HR] = 0.24; 95\% CI: 0.02-0.5, P = .02). For cohort 2, the median OS of patients with tumors with a low percentage of GA-hMSCs was 66 months, and for tumors with a high percentage, it was 11 months (HR = 0.38; 95\% CI: 0.13-0.9, P = .04). In the database of TCGA, the median OS times in patients with high and low coexpression levels of CD105/CD73/CD90 were 8.4 months and 13.1 months (HR = 0.4; 95\% CI: 0.1-0.88; P = .04), respectively. Conclusions: The percentage of GA-MSCs inversely correlates with OS, suggesting a role for GA-MSCs in promoting aggressive behavior of gliomas.",
optnote="PMID:28453745",
optnote="exported from refbase (http://demo.refbase.net/show.php?record=96589), last updated on Fri, 20 Oct 2017 10:21:27 +0200",
issn="1522-8517",
doi="10.1093/neuonc/now239",
opturl="http://www.ncbi.nlm.nih.gov/pubmed/28453745"
}